Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

CYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans

The Pharmacogenomics Journal volume 12, pages 176–183 (2012)Cite this article

Subjects

Abstract

CYP2D6 genotype and debrisoquine metabolic ratio (MR) were analyzed in 133 Nicaraguan Mestizos (NMs) and 260 Cubans divided into Cuban Mestizos (CMs) and White Cubans (WCs). The frequencies of poor metabolizers (MR⩾12.6) were 6% in NMs, 3.9% in CMs and 5.3% in WCs. The frequencies of ultrarapid metabolizers (MR⩽0.1) were 0% in NMs, 2.3% in CMs and 5.3% in WCs. Mean (±s.d.) MR among extensive metabolizers (MR<12.6) was higher in NMs (1.5±1.6; n=118) than in CMs (1.0±1.3; n=124; P<0.001) and WCs (0.7±1.0; n=124; P<0.001). MR correlated with the ‘activity score’ of CYP2D6 genotypes (P<0.05; r=−0.55). Mean MR was higher among NMs than WCs and CMs for groups classified as 1 (P<0.05) or 2 (P<0.01) ‘activity score’. In addition, mean (±s.d.) MR was higher among subjects carrying CYP2D6*17 than in CYP2D6 wt/wt (P<0.001). The CYP2D6*10 allele was higher in NMs (3.1%) than in CMs (0.8%; P<0.05) and WCs (0.4%; P<0.05). CYP2D6*17 allele was higher in CMs (10.2%) than WC (2.7%; P<0.005) and NMs (0%). Thus, the variability in CYP2D6 phenotypes found may be related to differences in allele frequency among groups (that is, CYP2D6*10 and *17 highest in NMs and CMs, respectively). However, the influence of environmental factors or alleles different than those studied here cannot be ruled out.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Ingelman-Sundberg M . Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 2005; 5: 6–13.

    Article  CAS  PubMed  Google Scholar 

  2. LLerena A, Cobaleda J, Martínez C, Benítez J . Interethnic differences in drug metabolism: influence of genetic and environmental factors on debrisoquine hydroxylation phenotype. Eur J Drug Metab Pharmacokinet 1996; 21: 129–138.

    Article  CAS  PubMed  Google Scholar 

  3. Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelman-Sundberg M . Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 1996; 278: 441–446.

    CAS  PubMed  Google Scholar 

  4. Bernard S, Neville KA, Nguyen AT, Flockhart DA . Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications. Oncologist 2006; 11: 126–135.

    Article  CAS  PubMed  Google Scholar 

  5. Kohlrausch FB, Gama CS, Lobato MI, Belmonte-de-Abreu P, Gesteira A, Barros F et al. Molecular diversity at the CYP2D6 locus in healthy and schizophrenic southern Brazilians. Pharmacogenomics 2009; 10: 1457–1466.

    Article  CAS  PubMed  Google Scholar 

  6. Isaza CA, Henao J, López AM, Cacabelos R . Isolation, sequence and genotyping of the drug metabolizer CYP2D6 gene in the Colombian population. Methods Find Exp Clin Pharmacol 2000; 22: 695–705.

    Article  CAS  PubMed  Google Scholar 

  7. Arias TD, Jorge LF, Lee D, Barrantes R, Inaba T . The oxidative metabolism of sparteine in the Cuna Amerindians of Panama: absence of evidence for deficient metabolizers. Clin Pharmacol Ther 1988; 43: 456–465.

    Article  CAS  PubMed  Google Scholar 

  8. Jorge LF, Eichelbaum M, Griese EU, Inaba T, Arias TD . Comparative evolutionary pharmacogenetics of CYP2D6 in Ngawbe and Embera Amerindians of Panama and Colombia: role of selection versus drift in world populations. Pharmacogenetics 1999; 9: 217–228.

    CAS  PubMed  Google Scholar 

  9. Muñoz S, Vollrath V, Vallejos MP, Miquel JF, Covarrubias C, Raddatz A et al. Genetic polymorphisms of CYP2D6, CYP1A1 and CYP2E1 in the South-Amerindian population of Chile. Pharmacogenetics 1998; 8: 343–351.

    Article  PubMed  Google Scholar 

  10. Mendoza R, Wan YJ, Poland RE, Smith M, Zheng Y, Berman N et al. CYP2D6 polymorphism in a Mexican American population. Clin Pharmacol Ther 2001; 70: 552–560.

    Article  CAS  PubMed  Google Scholar 

  11. Luo HR, Gaedigk A, Aloumanis V, Wan YJ . Identification of CYP2D6 impaired functional alleles in Mexican Americans. Eur J Clin Pharmacol 2005; 61: 797–802.

    Article  CAS  PubMed  Google Scholar 

  12. Casner PR . The effect of CYP2D6 polymorphisms on dextromethorphan metabolism in Mexican Americans. J Clin Pharmacol 2005; 45: 1230–1235.

    Article  CAS  PubMed  Google Scholar 

  13. López M, Guerrero J, Jung-Cook H, Alonso ME . CYP2D6 genotype and phenotype determination in a Mexican Mestizo population. Eur J Clin Pharmacol 2005; 61: 749–754.

    Article  PubMed  Google Scholar 

  14. Sosa-Macías M, Elizondo G, Flores-Pérez C, Flores-Pérez J, Bradley-Alvarez F, Alanis-Bañuelos RE et al. CYP2D6 genotype and phenotype in Amerindians of Tepehuano origin and Mestizos of Durango, Mexico. J Clin Pharmacol 2006; 46: 527–536.

    Article  PubMed  Google Scholar 

  15. LLerena A, Edman G, Cobaleda J, Benítez J, Schalling D, Bertilsson L . Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6. Acta Psychiatr Scand 1993; 87: 23–28.

    Article  CAS  PubMed  Google Scholar 

  16. Estevez F, Giusti M, Parrillo S, Oxandabarat J . Dextromethorphan O-demethylation polymorphism in the Uruguayan population. Eur J Clin Pharmacol 1997; 52: 417–418.

    Article  CAS  PubMed  Google Scholar 

  17. LLerena A, Dorado P, Peñas-Lledó EM . Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity. Pharmacogenomics 2009; 10: 17–28.

    Article  CAS  PubMed  Google Scholar 

  18. Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjöqvist F, Ingelman-Sundberg M . Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 1994; 46: 452–459.

    CAS  PubMed  Google Scholar 

  19. Masimirembwa C, Persson I, Bertilsson L, Hasler J, Ingelman-Sundberg M . A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity. Br J Clin Pharmacol 1996; 42: 713–719.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. LLerena A, Dorado P, Peñas-Lledó EM, Cáceres MC, De la Rubia A . Low frequency of CYP2D6 poor metabolizers among schizophrenia patients. Pharmacogenomics J 2007; 7: 408–410.

    Article  CAS  PubMed  Google Scholar 

  21. Sheng HH, Zeng AP, Zhu WX, Zhu RF, Li HM, Zhu ZD et al. Allelic distributions of CYP2D6 gene copy number variation in the Eastern Han Chinese population. Acta Pharmacol Sin 2007; 28: 279–286.

    Article  CAS  PubMed  Google Scholar 

  22. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS . The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 2008; 83: 234–242.

    Article  CAS  PubMed  Google Scholar 

  23. LLerena A, Herraíz AG, Cobaleda J, Johansson I, Dahl ML . Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents. Clin Pharmacol Ther 1993; 54: 606–611.

    Article  CAS  PubMed  Google Scholar 

  24. Peñas-LLedó EM, Dorado P, Pacheco R, González I, LLerena A . Relation between CYP2D6 genotype, personality, neurocognition and overall psychopathology in healthy volunteers. Pharmacogenomics 2009; 10: 1111–1120.

    Article  PubMed  Google Scholar 

  25. Agúndez JA, Ramirez R, Hernandez M, Llerena A, Benítez J . Molecular heterogeneity at the CYP2D gene locus in Nicaraguans: impact of gene-flow from Europe. Pharmacogenetics 1997; 7: 337–340.

    Article  PubMed  Google Scholar 

  26. González I, Pérez B, Alvarez M, Dorado P, LLerena A . Study of debrisoquine hydroxylation polymorphism (CYP2D6) in the Cuban population compared to Spaniards. Med Clin (Barc) 2007; 128: 772–774.

    Article  Google Scholar 

  27. González I, Peñas-Lledó EM, Pérez B, Dorado P, Alvarez M, LLerena A . Relation between CYP2D6 phenotype and genotype and personality in healthy volunteers. Pharmacogenomics 2008; 9: 833–840.

    Article  PubMed  Google Scholar 

  28. Dorado P, Berecz R, Cáceres MC, González I, Cobaleda J, Llerena A . Determination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship. Clin Chem Lab Med 2005; 43: 275–279.

    Article  CAS  PubMed  Google Scholar 

  29. Dahl ML, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjöqvist F . Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther 1995; 274: 516–520.

    CAS  PubMed  Google Scholar 

  30. Dorado P, Cáceres MC, Pozo-Guisado E, Wong ML, Licinio J, Llerena A . Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use. Biotechniques 2005; 39: 571–574.

    Article  PubMed  Google Scholar 

  31. Lou YC, Ying L, Bertilsson L, Sjöqvist F . Low frequency of slow debrisoquine hydroxylation in a native Chinese population. Lancet 1987; 2: 852–853.

    CAS  PubMed  Google Scholar 

  32. Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR et al. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985; 38: 402–408.

    Article  CAS  PubMed  Google Scholar 

  33. Sohn DR, Kusaka M, Shin SG, Jang IJ, Chiba K, Ishizaki T . Utility of a one-point (3-hour postdose) plasma metabolic ratio as a phenotyping test using metoprolol in two east Asian populations. Ther Drug Monit 1992; 14: 184–189.

    Article  CAS  PubMed  Google Scholar 

  34. Leathart JB, London SJ, Steward A, Adams JD, Idle JR, Daly AK . CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles. Pharmacogenetics 1998; 8: 529–541.

    Article  CAS  PubMed  Google Scholar 

  35. Wan YJ, Poland RE, Han G, Konishi T, Zheng YP, Berman N et al. Analysis of the CYP2D6 gene polymorphism and enzyme activity in African-Americans in southern California. Pharmacogenetics 2001; 11: 489–499.

    Article  CAS  PubMed  Google Scholar 

  36. Gaedigk A, Gotschall RR, Forbes NS, Simon SD, Kearns GL, Leeder JS . Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. Pharmacogenetics 1999; 9: 669–682.

    Article  CAS  PubMed  Google Scholar 

  37. Evans WE, Relling MV, Rahman A, McLeod HL, Scott EP, Lin JS . Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans. J Clin Invest 1993; 91: 2150–2154.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Masimirembwa C, Hasler J, Bertilsson L, Johansson I, Ekberg O, Ingelman-Sundberg M . Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population. Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs. Eur J Clin Pharmacol 1996; 51: 117–122.

    Article  CAS  PubMed  Google Scholar 

  39. Griese EU, Asante-Poku S, Ofori-Adjei D, Mikus G, Eichelbaum M . Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population. Pharmacogenetics 1999; 9: 715–723.

    CAS  PubMed  Google Scholar 

  40. Dandara C, Masimirembwa CM, Magimba A, Sayi J, Kaaya S, Sommers DK et al. Genetic polymorphism of CYP2D6 and CYP2C19 in east- and southern African populations including psychiatric patients. Eur J Clin Pharmacol 2001; 57: 11–17.

    Article  CAS  PubMed  Google Scholar 

  41. Gaedigk A, Bradford LD, Marcucci KA, Leeder JS . Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans. Clin Pharmacol Ther 2002; 72: 76–89.

    Article  CAS  PubMed  Google Scholar 

  42. Wennerholm A, Johansson I, Massele AY, Lande M, Alm C, Aden-Abdi Y et al. Decreased capacity for debrisoquine metabolism among black Tanzanians: analyses of the CYP2D6 genotype and phenotype. Pharmacogenetics 1999; 9: 707–714.

    Article  CAS  PubMed  Google Scholar 

  43. Panserat S, Sica L, Gérard N, Mathieu H, Jacqz-Aigrain E, Krishnamoorthy R . CYP2D6 polymorphism in a Gabonese population: contribution of the CYP2D6*2 and CYP2D6*17 alleles to the high prevalence of the intermediate metabolic phenotype. Br J Clin Pharmacol 1999; 47: 121–124.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Wennerholm A, Johansson I, Hidestrand M, Bertilsson L, Gustafsson LL, Ingelman-Sundberg M . Characterization of the CYP2D6*29 allele commonly present in a black Tanzanian population causing reduced catalytic activity. Pharmacogenetics 2001; 11: 417–427.

    Article  CAS  Google Scholar 

  45. Løvlie R, Daly AK, Matre GE, Molven A, Steen VM . Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism? Pharmacogenetics 2001; 11: 45–55.

    Article  PubMed  Google Scholar 

  46. Sachse C, Brockmöller J, Bauer S, Roots I . Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60: 284–295.

    CAS  PubMed  PubMed Central  Google Scholar 

  47. Bathum L, Johansson I, Ingelman-Sundberg M, Hørder M, Brøsen K . Ultrarapid metabolism of sparteine: frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by restriction fragment length polymorphism and long polymerase chain reaction. Pharmacogenetics 1998; 8: 119–123.

    Article  CAS  PubMed  Google Scholar 

  48. Suarez-Kurtz G, Pena SD . Pharmacogenomics in the Americas: the impact of genetic admixture. Curr Drug Targets 2006; 7: 1649–1658.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported by Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica (I+D+I) and Fondo Social Europeo of the European Union (FEDER), Instituto de Salud Carlos III-FIS CIBERSAM and CAIBER and Research Grants (PI06/1681; CP06/0030 to PD), Ministerio de Educación y Ciencia (SAF2006-13589), by AEXCID Cooperación Extremeña of the Junta de Extremadura (9IA006), and coordinated in the network Red Iberoamericana de Farmacogenética y Farmacogenómica (CYTED 206RT0290).

Author information

Author notes

  1. I González

    Present address: 5Current address: Hospital de Llerena, Servicio Extremeño de Salud SES, Spain.,

Authors and Affiliations

  1. CICAB-CAIBER Centro de Investigación Clínica, Hospital Universitario Servicio Extremeño de Salud SES, Facultad de Medicina Universidad de Extremadura, Badajoz, Spain

    A LLerena, P Dorado & E M Peñas-LLedó

  2. Facultad de Medicina, UNAM Universidad Autónoma Nacional de Nicaragua, León, Nicaragua

    R Ramírez

  3. Hospital Psiquiátrico de La Habana, La Habana, Cuba

    I González & L R Calzadilla

  4. Facultad de Medicina Calixto García, Instituto Superior de Ciencias Médicas de La Habana, La Habana, Cuba

    M Álvarez & B Pérez

Authors
  1. A LLerena
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P Dorado
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R Ramírez
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. I González
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Álvarez
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E M Peñas-LLedó
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. B Pérez
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. L R Calzadilla
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A LLerena.

Ethics declarations

Competing interests

The authors declared no conflict of interest.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Cite this article

LLerena, A., Dorado, P., Ramírez, R. et al. CYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans. Pharmacogenomics J 12, 176–183 (2012). https://doi.org/10.1038/tpj.2010.85

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/tpj.2010.85

Keywords

This article is cited by

Search

Advanced search

Quick links